Panbela Therapeutics Stock Z Score
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Panbela |
Panbela Therapeutics Company Z Score Analysis
Panbela Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Panbela Therapeutics Z Score | -49.78 |
Most of Panbela Therapeutics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Panbela Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionBased on the company's disclosures, Panbela Therapeutics has a Z Score of -49.78. This is 837.48% lower than that of the Biotechnology sector and notably lower than that of the Health Care industry. The z score for all United States stocks is notably higher than that of the company.
Panbela Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Panbela Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Panbela Therapeutics could also be used in its relative valuation, which is a method of valuing Panbela Therapeutics by comparing valuation metrics of similar companies.Panbela Therapeutics is currently under evaluation in z score category among its peers.
Panbela Fundamentals
| Return On Equity | -7.98 | ||||
| Return On Asset | -1.92 | ||||
| Current Valuation | 8.64 M | ||||
| Shares Outstanding | 3.48 M | ||||
| Shares Owned By Institutions | 0.59 % | ||||
| Number Of Shares Shorted | 106.97 K | ||||
| Price To Book | 3.22 X | ||||
| EBITDA | (34.76 M) | ||||
| Net Income | (34.93 M) | ||||
| Cash And Equivalents | 2.53 M | ||||
| Cash Per Share | 0.12 X | ||||
| Total Debt | 6.84 M | ||||
| Current Ratio | 0.56 X | ||||
| Book Value Per Share | (16.57) X | ||||
| Cash Flow From Operations | (15.28 M) | ||||
| Short Ratio | 0.07 X | ||||
| Earnings Per Share | (157.02) X | ||||
| Target Price | 410.0 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 3.93 M | ||||
| Total Asset | 4.98 M | ||||
| Retained Earnings | (91.09 M) | ||||
| Working Capital | (6.06 M) | ||||
| Z Score | -49.78 | ||||
| Net Asset | 4.98 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Panbela Stock
If you are still planning to invest in Panbela Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Panbela Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |